Headlines This Week - March 30 - April 5, 2025

From changes in international psychiatric services to new psychopharmacology data, discover the news making headlines in psychiatry.

Positive Interim Results for Alzheimer Treatment. Roche announced promising interim phase 1/2A results for trontinemab, its novel anti-amyloid beta antibody using BrainShuttle technology. Designed to enhance drug delivery across the blood-brain barrier, trontinemab demonstrated dose-dependent reductions in amyloid plaque levels in patients with early Alzheimer disease. The results were presented at at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases.

Levi Garraway, MD, PhD, chief medical officer and head of global product development for Roche, commented in a statement to the press: “We are pleased with the progress across our [AD] portfolio as we move ahead with a phase 3 trontinemab programme and continue to expand our diagnostic solutions.”